08 Jan Exact Sciences’ stock soars after it says Cologuard tests near 1 million for 2018
Exact Sciences Corp. stock climbed nearly 15 percent Monday after the Madison cancer diagnostics company offered preliminary results for the last three months of 2018 that topped projections, showing more than 930,000 people used Exact’s Cologuard home test kit for colorectal cancer last year. Revenue for...